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Thiolation of immunoglobulin G (IgG) with I)L-N-acetylhomocysteinethiolactone, 
catalyzed by 2-pyridinealdoxime methiodide, incorporated new sulfur groups into IgG. 
Triaziquinone was subsequently conjugated to the sulfur groups. Triaziquinone-IgG 
complex retained the alkylating activity of the drug and the immunological activity of 
the antibody. The conjugation procedure was inhibited by the thiol-blocking agent 
methyl methanethiolsulfonate. 
INTRODUCTION 
The immunologic response to certain diseases appears ineffective as a 
means of control and chemotherapy of disease often carries the hazard 
of systemic toxicity. These two problems could potentially be reduced by 
conjugating a chemotherapeutic compound to appropriate antibody. Hope- 
fully, the antibody would carry the chemotherapeutic agent to the target 
antigen within the host. Therefore, antibodies would become more specifi- 
cally cytotoxic while simultaneously diminishing the systemic toxicity 
associated with many chemotherapeutic agents. 
This type of chemoimmunotherapy, conceived by Paul Ehrlich in 1906 
(Ehrlich, 1906), has been evaluated with viral, bacterial, parasitic and neo- 
plastic models. As reviewed by Rubens (1974), agents successfully con- 
jugated and 'targeted' by antibodies have included various cytotoxic drugs, 
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radioisotopes, boron, toxins and enzymes. Recently triaziquinone has been 
conjugated by a reduction procedure to antibodies directed to sarcoma 
tumor cells (Linford et al., 1974). 
Potential problems exist in conjugating triaziquinone to immunoglobulin 
G (IgG) by a reduction process that relies on sulfur groups already present 
in IgG (Linford et al., 1974). The reduction procedure could weaken or 
completely degrade the IgG polypeptide into its component peptides if 
the process preferentially reduced the interchain rather than intrachain 
disulfide bonds. Interchain disulfide bonds are generally more susceptible 
to the effects of reducing agents than intrachain disulfide bonds (Konigsberg, 
1972). Even though antibody specificity may return upon oxidation of 
reduced antibody fragments (White, 1972a), the procedure may decrease a 
portion of the immunological activity of the antibody. A loss of specific 
antibody activity would increase the significance of the cytotoxicity con- 
tributed by triaziquinone when bound to IgG of different specificities. 
The cytotoxicity of drug bound to non-specific IgG does not depend on 
a firm attachment of the complex to an antigen of a target cell (Linford 
and Froese, 1978). 
A procedure is described in this report which conjugates triaziquinone 
to new sulfur groups on IgG (Fig. 1). The new sulfur groups are incorporated 
into the IgG molecule by a protein thiolation process involving DL-N-acetyl- 
homocysteinethiolactone (White, 1972b). 2-Pyridinealdoxime methiodide 
catalyzes the reaction to favor the successful thiolation of the protein and 
to decrease the hydrolytic degradation of DL-N-acetylhomocysteinethio- 
lactone (Klotz and Elfbaum, 1964). The triaziquinone-IgG complex retains 
the alkylating activity of the drug and the immunological activity of the 
antibody. The conjugation procedure is inhibited by the introduction 
of the thiol-blocking agent, methyl methanethiolsulfonate, immediately 
after the protein is thiolated by DL-N-acetylhomocysteinethiolactone. 
MATERIALS AND METHODS 
Virus production and purification 
Influenza A/AA/6/60 H2H2 was obtained from Dr. Hunein F. Maassab, 
Department of Epidemiology, School of Public Health, The University of 
Michigan. It was originally isolated from a throat washing which was used to 
infect a chick kidney monolayer. The virus was subsequently passed 24 times 
in the allantoic cavity of chicken eggs. 
A pool of virus was produced from the stock virus by propagating the 
virus in the allantoic cavity of fertile eggs. The stock virus possessed a 1024 
hemagglutinating titer per 0.025 ml and had an EIDs0 (50% egg infectious 
dose) of 10 -7 as measured by the Reed-Muench technique (Reed and 
Muench, 1938). A 10 -7 dilution of stock virus was prepared in 0.3% nutrient 
broth, containing 100 U/ml of penicillin and 200 pg/ml of streptomycin. 
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A 0.1 ml volume of the diluted virus was inoculated into the allantoic cavity 
of viable l l~lay-old Heisdorf-Nelson eggs (Singing Hills Poultry Farm, 
Manchester, MI). The allantoic fluid was collected after 3 days of incubation 
at 35°C. These virus pools had a 1024 to 2048 hemagglutinating titer per 
0.025 ml and an EIDs0 of 10 -7 as measured by the Reed-Muench technique. 
The virus was purified by adsorption and elution with a 5% (by volume) 
suspension of chicken erythrocytes, followed by differential centrifugation 
at 5000 X g for 10 min and 75,000 X g for 1 h. The viral pellet was sonicated 
for 10 min at an output current of 1.0 A in a Raytheon sonic oscillator 
(Raytheon Manufacturing Company, Waltham, MA). The sonicated viral 
pellet was purified further by isopycnic centrifugation at 60,000 X g for 
18 h in a 10--60% (w/v) continuous sucrose gradient. 
Virus quantitation 
Virus hemagglutinin was quantitated by the microhemagglutination 
assay (Sever, 1962). Infective virus was quantitated by the 50% egg infective 
dose assay (Reed and Muench, 1938). 
Antibody production and purification 
Male, New Zealand White rabbits (Johnson Rabbitry, Coldwater, MI), 
weighing approximately 5 lb, were used for production of antibody "to 
purified influenza virus. Purified virus pooled from the isopycnic gradient 
that formed the peak between 1.1800 g/ml and 1.2000 g/ml, with a micro- 
hemagglutinating titer of 1024 per 0.025 ml, was injected into a lateral ear 
vein. A 2.0 ml primary injection was followed 1 week later by a 1.0 ml 
secondary injection. Subsequent injections of 1.0 ml were given every few 
months. Animals were bled weekly from a medial ear artery. 
IgG was isolated from equilibrated serum by ion-exchange chromatog- 
raphy (Joustra and Lundren, 1969) with QAE Sephadex A-50 (Pharmacia 
Fine Chemicals Inc., Piscataway, NJ). Eluted IgG was concentrated in an 
Amicon model 52 stirred cell (Amicon Corporation, Lexington, MA) with 
an Amicon XM 100A anisotropic filter. The concentrated material was 
lyophilized and hermetically sealed in glass ampules. 
Purity of the I~G was examined by slide immunoelectrophoresis (Williams 
and Chase, 1968). Purified IgG formed one line of precipitation of analogous 
position with either goat antiserum to rabbit whole serum (Microbiological 
Associates, Bethesda, MD) or goat antiserum to the heavy chain of rabbit 
IgG (Cappel Laboratories, Downingtown, PA). 
Antibody quan titation 
The presence of antibody to influenza virus was measured by the micro- 
hemagglutination inhibition assay (Sever, 1962). The amount of protein 
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contained in an IgG preparation was determined spectrophotometr ical ly 
with a Beckman Acta Three spect rophotometer  (Beckman Instrument 
Inc., Fullerton, CA) using a 280 nm and 260 nm nomograph (California 
Corporation for Biochemical Research, Los Angeles, CA). 
Reduction procedure of conjugating triaziquinone to IgG 
The reduct ion procedure (Linford et al., 1974) to conjugate triaziquinone 
(2,3,5-tr is-ethylenimino-l ,4-benzoquinone) to ant ibody was tried initially. 
The triaziquinone was obtained from Bayer Pharmaceuticals (Fahrenfabriken 
Bayer, Leverkusen, F.R.G.) and from the Drug Research and Development  
Division of  the National Cancer Institute. Several alterations (from personal 
communicat ions by Dr. J.H. Linford) were incorporated in the procedure.  
These alterations included: variation of the dithiothreitol (Calbiochem, 
San Diego, CA) concentrat ion from 100 mM to 600 mM; using different lots 
of  dithiothreitol;  decreasing the incubation time with dithiothreitol from 
90 to 15 min; more rapid removal of the excess dithiothreitol  from the reac- 
tion mixture by  chromatography on Bio Gel P-30 (Bio Rad Laboratories, 
Richmond,  CA); and by  adding a 2.0 M glucose concentrat ion (Calbiochem, 
San Diego, CA) to the IgG before being exposed to the reducing agent. 
Thiolation procedure of conjugating triaziquinone to IgG 
A buffer of 0.1 M ammonium bicarbonate and 0.002 M ethylenediamine- 
tetraacetic acid tetrasodium salt was prepared with double distilled water. 
The water was previously deoxygenated by  boiling for 1 h and percolating 
with nitrogen gas for 1 h. This process removed 92% of  the oxygen from the 
water as determined by the azide modification of  the Winkler assay (Amer- 
ican Public Health Association et al., 1975).  A 200 mM 2-pyridinealdoxime 
methiodide (Aldrich Chemical Company Inc., Milwaukee, WI) and 0.125 mM 
IgG solution was prepared in the deoxygenated buffer,  and enough DL-g- 
acetylhomocyste inethiolactone (Aldrich Chemical Company Inc., Mil- 
waukee,  WI) was added to this mixture to form a 250 mM concentration.  
The reaction mixture was incubated 4 h at 4°C with stirring. Nitrogen gas 
was continuously introduced into the reaction vessel. The pH was adjusted 
to 9.0 at 30 min intervals by a 5% trimethylamine solution (Matheson, 
Coleman and Bell Manufacturing Chemists, Norwood,  OH), which was 
also prepared in the deoxygenated buffer.  After incubation,  the mixture 
was dialyzed overnight against 3 changes of 300 ml of  deoxygenated buffer. 
An equal volume of  4.3 mM triaziquinone was prepared in deoxygenated 
phosphate buffer  and added to the reaction mixture under a nitrogen atmo- 
sphere. The reaction vessel was sealed and placed in a 37°C water bath for 
4 h after which the mixture was dialyzed overnight against 3 changes of  
300 ml of phosphate buffer.  
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Alkylation assay of drug activity 
The alkylating activity of  the triaziquinone was measured by the quater- 
nization reaction (Linford, 1973). The only modification of the procedure 
was the use of an undiluted 1.0 ml sample of any preparation containing 
triaziquinone. 4-(p-nitrobenzyl)-pyridine was obtained from Aldrich Chem- 
icals, Milwaukee, WI; 1,2-propanediol and triethylamine were obtained from 
Matheson, Coleman and Bell Manufacturing Chemists, Norwood, OH. 
Blockage of sulfur groups 
The thiol-blocking agent, methyl  methanethiolsulfonate (Aldrich Chemical 
Company Inc., Milwaukee, WI), was used to analyze the mechanism by 
which the thiotation process conjugated triaziquinone to IgG (Smith et al., 
1975). 
RESULTS 
Repeated efforts to conjugate triaziquinone to IgG by the reduction 
procedure were unsuccessful. The authors believe that  the reducing agent, 
dithiothreitol,  was denaturing the IgG molecule by the preferential reduction 
of the more susceptible interchain disulfide bonds (Konigsberg, 1972). If a 
random reoxidation of  these interchain bonds occurred as the dithiothreitol 
was removed from the reaction mixture by dialysis, it could explain the 
observable precipitate that  was formed and the unavailability of the sulfur 
groups in IgG to bind the sixth carbon of the triaziquinone molecule as 
hypothesized by Linford (1973). 
Therefore, the thiolation procedure depicted in Fig. 1 was developed 
to conjugate triaziquinone to IgG. With the thiolation method,  the quater- 
nization assay for alkylating drugs detected the presence of 0.43 mM of 
active triaziquinone associated with IgG (Table 1). This represented an 
average of 7 active triaziquinone groups on each IgG molecule. If the IgG 
was not  previously thiolated by 250 mM of DL-N-acetylhomocystein- 
ethiolactone, no triaziquinone was found associated with the IgG. When 
200 mM of 2-pyridinealdoxime methiodide was omitted from the thiolation 
procedure, 0.31 mM of drug was bound to IgG (Table 1). The absence of 
catalyst from the reaction produced a 25% decrease in the amount  of  drug 
conjugated to antibody. 
Conjugation of triaziquinone to IgG by the thiolation procedure was 
prevented by the introduction of a thiol-blocking agent immediately after 
the protein was thiolated by DL-N-acetylhomocysteinethiolactone. Thiolated 
IgG was exposed to 1.62 mM of methyl methanethiolsulfonate for 30 min 
at 4°C. After the  excess methyl  methanethiolsulfonate was removed by 
overnight dialysis against deoxygenated buffer, the quaternization assay 
detected no subsequent binding of triaziquinone to IgG (Table 2). The 
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TRIAZIQUINONE CONJUGATED TO l.gG 
Fig. 1. Diagram of the hypothesized mechanism by which the thiolation procedure 
conjugates triaziquinone to IgG. The ring of the thiolating agent, DL-N-acetylhomo- 
cysteinethiolactone (AHTL), is opened by 2-pyridinealdoxime methiodide (PAM). The 
thiolating agent introduces a new sulfur on the IgG molecule which subsequently binds 
the triaziquinone. 
lack of  detectable triaziquinone on the IgG molecule was not  caused by 
direct inactivation of the drug by the thiol-blocking agent. When triazi- 
quinone was directly exposed to methyl  methanethiolsulfonate,  0 .43 mM of 
triaziquinone (100  pg/ml) was not  measurably inactivated even after 1 h of 
exposure to 1 .62 mM of  methyl  methanethiolsulfonate  at 25°C. If IgG 
was exposed to the thiol-blocking agent before the antibody was thiolated, 
only  a 20% decrease was observed in the subsequent amount  of triaziquinone 
conjugated to IgG. 
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Effect of methyl methanethiolsulfonate on the thiolation of IgG and subsequent conjuga- 
tion to triaziquinone 
Time of exposure to MMTS Bound triaziquinone Per cent inhibition 
(pg/ml) d of conjugation 
No exposure a 64 0 
Before thiolation of IgG b 51 20 
After thiolation of IgG c 0 100 
a Triaziquinone was conjugated to IgG by the thiolation procedure. 
b IgG was exposed to 1.62 mM of methyl methanethiolsulfonate (MMTS) for 30 rain at 
4°C before the IgG was thiolated by the thiolation procedure. 
c IgG was exposed to 1.62 mM of methyl methanethiolsulfonate (MMTS) for 30 min at 
4°C after the IgG was thiolated by the thiolation procedure. 
d The amount of triaziquinone subsequently conjugated to the IgG by thiolation was 
determined by the quaternization reaction. 
IgG was  e x a m i n e d  b y  t h e  m i c r o h e m a g g l u t i n a t i o n  i n h i b i t i o n  assay.  T h e  
a n t i - i n f l u e n z a  IgG a n d  t r i a z i q u i n o n e - c o n j u g a t e d  a n t i - i n f l u e n z a  IgG h a d  t h e  
s a m e  a n t i b o d y  t i t e r  o f  64  pe r  0 . 0 2 5  m l  as d e t e r m i n e d  b y  t h e  i n h i b i t i o n  
assay ( T a b l e  3).  I f  t h e  t e m p e r a t u r e  o f  t h e  t h i o l a t i o n  r e a c t i o n  was  r a i sed  
t o  2 5 ° C ,  t h e  assay  d e t e c t e d  a d e c r e a s e  in  a n t i b o d y  a c t i v i t y  f r o m  16  a n d  32 
t o  a t i t e r  o f  8 a n d  16  p e r  0 . 0 2 5  ml .  T h e  c o n j u g a t i o n  o f  d r u g  t o  n o n - s p e c i f i c  
TABLE 3 
Effect of the conjugation process on the immunological activity of antibody 
Type of Antibody Thiolation IgG 
antibody a conjugated to temperature b (mg/ml) c 
triaziquinone ( ° C) 
Antibody titer 
per 0.025 ml d 
Influenza No 4 8.0 64, 64 
Influenza Yes 4 8.0 64, 64 
Non-specific No 25 8.4 0, 0 
Non-specific Yes 25 8.4 0, 0 
Influenza No 25 8.4 16, 32 
Influenza Yes 25 8.4 8, 16 
a IgG was purified by ion-exchange chromatography with QAE Sephadex A-50 from nor- 
mal rabbit serum or from rabbits immunized with influenza virus. 
b Triaziquinone was conjugated to IgG by the thiolation procedure. One batch of IgG was 
thiolated at 4°C and another batch of IgG was thiolated at 25°C. 
c IgG concentration was determined spectrophotometrically by using a 280 nm and 260 
nm nomograph. 
d Immunological activity of antibody was measured in duplicate by microhemagglutina- 
tion inhibition. 
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IgG did not induce the IgG to adsorb influenza virus. Both the non-con- 
jugated non-specific IgG and non-specific IgG conjugated to triaziquinone 
had antibody titers of 0. 
DISCUSSION 
The significance of this exciting area of chemoimmunotherapy research 
is that various types of cytotoxic agents could potentially be conjugated 
to antibodies. Even the multitude of cytotoxic drugs that have never reached 
the stage of clinical trial, or those removed from the pharmaceutical market 
because of unforeseen systemic toxicity problems, may be satisfactory 
agents for chemoimmunotherapy. Relying on the immunological specificity 
of the antibody, the cytotoxic agent would be preferentially delivered 
to the site of the target antigen in the patient. The target could either be 
a viral, bacterial, parasitic, or neoplastic antigen. 
During the preparation of cytotoxic agents conjugated to antibody 
carriers, one must be careful to preserve the cytotoxic quality of the cyto- 
toxic agent as well as the immunological activity of the antibody. Because a 
reduction procedure of conjugating IgG and triaziquinone (Linford et al., 
1974) may lead to a random reoxidation and subsequent denaturation of the 
peptide components of IgG, a new thiolation procedure was developed, as 
described here, which relies on exogenous instead of the endogenous sulfur 
groups in IgG. 
The thiolation procedure apparently conjugated 0.43 mM of active triazi- 
quinone to IgG as determined by the quaternization assay for alkylating 
drugs (Fig. 1). Unless the IgG was previously thiolated by DL-N-acetyl- 
homocysteinethiolactone, the quaternization assay detected no active drug 
bound to the IgG (Table 1). This implies that the conjugation of triazi- 
quinone to IgG was not a result of adsorption of the drug to the protein. 
The hypothesized mechanism of the binding of drug by the new sulfur 
groups was confirmed by experiments involving the thiol-blocking agent 
(Smith et al., 1975). When thiolated IgG was exposed to 1.62 mM of methyl 
methanethiolsulfonate, no triaziquinone was subsequently detected on the 
IgG molecule by the quaternization reaction (Table 2). Presumably the 
sulfur groups incorporated into the IgG molecule by DL-N-acetylhomo- 
cysteinethiolactone were not available to link the triaziquinone. The absence 
of detectable drug bound to the antibody in these experiments was not 
explainable by methyl methanethiolsulfonate directly inactivating the 
triaziquinone, since a 1.62 mM concentration of the blocking agent did 
not completely inactivate the alkylating activity of 0.43 mM (100 pg/ml) 
of the drug. When IgG was exposed to the thiol-blocking agent before 
the initiation of thiolation procedure, there was a 20% decrease in the 
amount of drug subsequently bound to IgG (Table 2). That 20% decrease 
probably represents a steric hindrance of the thiolation procedure by the 
thiol-blocking agent binding to accessible sulfur groups originally present 
in the antibody. 
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Whereas the Linford process relies on the reduction of endogenous sulfur 
groups in the IgG structure (Linford et al., 1974), the conjugation of triazi- 
quinone to IgG, by using a thiol bridge, relies on previously published 
thiolation reactions to incorporate new sulfur groups into the IgG molecule. 
The other proteins thiolated by DL-N-acetylhomocysteinethiolactone have 
included glycine (Benesch and Benesch, 1956), bovine serum albumin 
(Singer et al., 1960), ovalbumin (Singer et al., 1960), alpha chymotryp- 
sinogen (Abadi and Wilcox, 1960), ribonuclease (Singer et al., 1960; White 
and Sandoval, 1962), insulin (Virupaksha and Tarver, 1964), and gelatin 
(Klotz and Elfbaum, 1964}. Thiolated antibodies have been used as specific 
immunoadsorbents by subsequently cross-linking the new sulfur groups 
into disulfide bridges (Stephen et al., 1966; Chidlow et al., 1967; Wood 
et al., 1968). An average of 8--9 sulfur groups were incorporated on each 
IgG molecule in the antibody immunoadsorbents, although the 
range could be extended from 5 to 20 sulfur groups by varying the reaction 
conditions. The ability of 7 triaziquinone molecules to bind to 7 new sulfur 
groups, introduced by the thiolation procedure, is shown by our results 
in Table 1. The results, from either the reduction or thiolation process, is 
that the sulfur groups apparently provide a site for subsequent binding 
of the sixth carbon of the triaziquinone compound as hypothesized by 
Linford (1973). 
The conditions of the present thiolation procedure did not favor sub- 
sequent disulfide bond formation by the new sulfur groups. The boiling and 
percolation of the aqueous solutions with nitrogen gas, as well as the 
nitrogen atmosphere in the reaction vessel, inhibited the oxidation of the 
new sulfur groups (Virupaksha and Tarver, 1964; Stephen et al., 1966; 
White, 1972a, b). Furthermore, ethylenediaminetetraacetic acid was 
present to chelate metals that might catalyze the oxidation of sulfur (Konigs- 
berg, 1972). Disulfide bond formation by the presence of high protein 
concentration was avoided by using 0.062 mM protein concentrations 
(Stephen et al., 1966; White, 1972a). The reaction conditions also avoided 
the problem of intermolecular and intramolecular bond formation by the 
new sulfur groups with the sulfur groups already present on IgG (White and 
Sandoval, 1962). 
The ammonium bicarbonate buffer was the first and only buffer utilized 
in the study since it was the buffer chosen by the initial investigators who 
thiolated proteins with acetylhomocysteinethiolactone (white and Sandoval, 
1962; white, 1972b). Another buffer was never sought since triaziquinone 
was succesfully conjugated to IgG while using this buffer. Any nucleophilic 
character of this buffer would probably be overshadowed in the thiolation 
procedure by the pyridinealdoxime methiodide, the imidazole catalyst, 
which itself is known as a nucleophile (Klotz and Elfbaum, 1964). 
The reaction conditions favored the successful thiolation of IgG by the 
aminolysis of DL-N-acetylhomocysteinethiolactone in comparison to the 
destructive hydrolysis of the thiolating agent. Since imidazole type com- 
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pounds can split thioester linkages, 2-pyridinealdoxime methiodide was 
added as a catalyst to form an active acylimidazole intermediate by opening 
the ring of DL-N-acetylhomocysteinethiolactone (Klotz and Elfbaum, 
1964). A 25% increase in the amount of triaziquinone bound to IgG was 
observed by the addition of the catalyst to the reaction (Table 1). Imidazole 
catalysts are made more effective by increasing the pH of the reaction to 
9 (Klotz and Elfbaum, 1964). The 5% trimethylamine buffer has great 
buffering capacity at the alkaline pH (White and Sandoval, 1962). High pH 
also hinders the hydrolytic degradation of thiolating agents (Benesch and 
Benesch, 1956). The 4°C temperature of the reaction favored aminolysis 
since the temperature coefficient of the rate of aminolysis is small (Benesch 
and Benesch, 1956). 
Thiolated antibodies retain their immunological activity (Stephen et al., 
1966; Chidlow et al., 1967; Wood et al., 1968). The binding of triaziquinone 
to the new sulfur groups apparently did not affect the antibody's reactivity 
to influenza virus. The non-conjugated IgG and IgG conjugated to triazi- 
quinone had the same titer of 64 per 0.025 ml, as determined by the micro- 
hemagglutination inhibition assay (Table3). DL-N-acetylhomocysteine- 
thiolactone can bind the epsilon or alpha nitrogen of proteins (White, 
1972a). Since thiolated IgG prepared at 4°C retained the immunological 
activity that is associated near the alpha nitrogen position, the thiolating 
agent was probably bound to the epsilon nitrogen of IgG. Even though 
the alpha nitrogen may be somewhat distant from the actual antibody 
combining site, the conjugation of a large prosthetic group to this area 
of the antibody structure, consisting of a thiol bridge and triaziquinone 
molecule, could still be near enough to the actual combining site of the 
IgG to have deleteriously affected its affinity and avidity. Indeed, the partial 
loss of immunological activity of the conjugation products prepared at 
25°C may be possibly explained, in part, by thiol and triaziquinone groups 
being able to bind to the less reactive alpha nitrogens of IgG at this elevated 
reaction temperature (Table 3). The thiolation procedure's predilection 
for the epsilon position may have been expected since the epsilon amino 
groups are generally more basic or nucleophilic (Lawton, R.G., personal 
communication, 1977) as well as usually occurring more often in proteins 
than alpha amino groups. The conjugation of triaziquinone to thiolated 
IgG did not cause non-specific IgG to adsorb influenza virus. Neither the 
non-specific IgG, nor non-specific IgG conjugated to triaziquinone, bound 
influenza virus, as determined by the microhemagglutination assay (Table 3). 
Thiolated antibodies used as specific immunoadsorbents have not adsorbed 
proteins non-specifically (Stephen et al., 1966; Chidlow et al., 1967; Wood 
et al., 1968). 
Our immediate interest is to analyze the activity of the conjugation 
product on tumor cells in vitro by conjugation triaziquinone to anti-tumor 
immunoglobulin G. If any enhancement in specific cytotoxicity is exhibited 
by the conjugation product in comparison to treatment of the target cells 
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with t r i az iqu inone  and an t i - tumor  a n t i b o d y  no t  con juga ted  together ,  anti- 
t u m o r  a n t i b o d y  alone or  t r iaz iquinone  alone,  the  th io la t ion  process  as well 
as the con juga t ion  p r o d u c t  will be character ized fur ther .  This will include 
the analysis of  the  o p t i m u m  reac t ion  cond i t ions  for  the  th io la t ion  p rocedure  
to  retain the a lkyla t ing and immunolog ica l  act ivi ty o f  the  conjuga t ion  
p r o d u c t ,  the n u m b e r  and loca t ion  o f  new thiol  groups i n t roduced  in the  
IgG molecule  by  using El lman 's  reagent  and amino  acid analysis, and the  
n u m b e r  and loca t ion  of  active as well as inactive t r iaz iquinone  groups sub- 
sequent ly  con juga ted  to  these thiol  groups.  
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